By Shaun Heasley
New federal data suggests that the number of children born with cerebral palsy is largely steady though some kids are at higher risk than others for the developmental condition.
About 2.2 out of 1,000 children born in 2002 were diagnosed with congenital cerebral palsy – stemming from brain damage before or during birth – according to findings published online Wednesday in the journal Pediatrics.
That’s a slight increase over the 1.9 per 1,000 identified for children born in 1985, researchers said.
Read the full story.
By Stephen Luke
A 2-year-old San Diego girl who received a stem cell infusion of her own umbilical cord blood, banked at birth, is giving new hope to parents of children with brain injuries.
Doctors have used cord blood for decades to help with blood disorders and some other diseases, but now a handful of new studies show those same cells can travel up to baby’s brain and heal injured areas.
The ramifications could impact everything from autism to cerebral palsy.
Ava Johnson, born with cerebral palsy, had limited use of the entire left side of her body. She didn’t use her left hand and couldn’t walk at 18 months until an experimental treatment changed everything, according to her parents.
Read the Full Story.
By Cord Blood Registry, Inc.
The purpose of this study is to compare the safety and effectiveness of two types of stem cells,(either banked cord blood or bone marrow), in children between the ages of 2 to 10 years with CP. 15 children with banked cord blood at CBR and 15 children without banked cord blood will be enrolled into the study. The study involves one baseline/treatment visit and 3 follow-up visits at 6 months, 12 months, and 2 years. Five children in each group will be randomized to a placebo control group at the baseline/treatment visit. Parents will not be told if their child received stem cells or a placebo until the 12 month follow-up visit. At that time parents may elect to have their child receive the stem cell treatment; either bone morrow harvest or umbilical cord blood if banked with CBR. All study visits will be conducted at the UTHealth Medical School and Children’s Memorial Hermann Hospital in Houston, Texas.
Primary Outcome Measures:
To determine if autologous cells using either BMMNCs or hUCBs are safe to administer in children with CP by assessing change at multiple time points. [Time Frame: All study visits from baseline to the end of study visit at year 2.] [Designated as safety issue: Yes]
In-hospital infusion toxicity: pulmonary and hepatic function; new seizures, hemorrhagic lesions or ischemic lesions on imaging.(Composite Outcome Measure)
Long-term safety: development of new mass lesions or other pathological structural changes; worsening neurological status.(Composite Outcome Measure)
Read the full story.